Sexually Transmitted Diseases

Introducing HIV screening in primary care offices has the potential to save lives and decrease the costs associated with treatment by increasing rates of early diagnosis.

In a recent editorial, Matthew Barnhart MD, MPH, medical officer for the US Agency for International Development (USAID) explored 5 new HIV drugs that are in the pipeline.

Benjamin Young, MD, PhD, discusses the four partners behind the Fast-Track Cities Initiative.

Pedro Cahn, MD, explains the new formulation of raltegravir HD.

Kathleen Squires, MD, explains how HIV treatment has changed since the 1980s.

Nader Pourhassan, PHD, president and chief executive officer of CytoDyn, the biotechnology company that acquired PRO 140, offers insight into the antibody as treatment for HIV.

Lynne Mofenson, MD, shares an update on the health burden of mother-to-child transmission (MTCT) of HIV.

Jake Glaser discusses how generating interest for the response to HIV and AIDS has changed since the 1990s.

Due to concerns that the use of PrEP might hinder clinicians from detecting HIV in infected individuals or lead to the development of resistant strains of HIV, scientists studied how PrEP affects seroconversion after HIV is acquired.

A phase 2a clinical trial has found the dapivirine vaginal ring to be a safe and acceptable means for HIV prevention in adolescents, who showed notably high adherence when using the ring.

The NIH has released the findings of the first of 2 early-stage clinical trials on assessing the safety and effectiveness of HIV candidate vaccinations that support additional development of vaccines.

As the IAS Conference on HIV Science wraps up this week, this Public Health Watch report takes a closer look at the challenges that remain when it comes to treating HIV.

Phase 2 study finds that the use of daily oral Truvada as a means of HIV prevention is safe and acceptable.

Peter Williams, PhD, discusses the LATTE-2 trial for HIV treatment.

Magda Opsomer, MD, explains why darunavir may be more beneficial than other HIV medications.

Researchers reported at the 9th IAS Conference on HIV Science that a HIV-infected child who had been treated in infancy has maintained remission without drugs since 2008.

Ariane van der Straten, PhD, MPH, explains the different attributes of administering pre-exposure prophylaxis via a HIV biomedical implant.

A recent study finds that the majority of HIV-infected transgender women are anxious about taking ART and feminizing hormone therapy simultaneously due to hazardous drug interactions.

Leah Johnson, PhD, discusses the biomedical HIV prevention implant that is being developed by RTI International.

Kenneth Mayer, MD, explains why tenofovir alafenamide may be the future of pre-exposure prophylaxis.

WHO and IAS come together to create the first-ever global research prioritization agendas at the 9th IAS Conference on HIV Science in Paris, France.

The results of a phase 2 trial for a 2-drug regimen of long-acting cabotegravir and rilpivirine and a 3-drug regimen in patient with HIV showed comparable viral suppression rates at 96 weeks.

Researchers from Dartmouth College’s Geisel School of Medicine have found that pregnant women with a history of HSV-1 maintain active antibodies against the virus that can be passed on to their newborns.

The World Health Organization (WHO) recently sent out a global alert warning of the growing threat of resistance to HIV drugs.

A systematic review analyzes the opportunity to provide coordinated care for HIV and noncommunicable conditions.